早期肺癌立体定向放疗中个体化PTV边距降低胸壁毒性
该回顾性研究纳入225例I期非小细胞肺癌患者共260个肿瘤,采用4D-CT计划、ITV均匀外扩5mm生成PTV并去除与胸壁重叠部分,中位随访36.8个月,1-2级胸壁毒性总体发生率2.2%,距胸壁5mm内肿瘤为2.8%,无3/4级毒性,3年局部控制率92.1%。
要点
- PTV沿胸壁截断后1-2级胸壁毒性仅2.2%,距胸壁5mm内肿瘤为2.8%。
- 无3/4级胸壁毒性,3年局部控制率92.1%(95%CI 87.4%-96.8%)。
- 该技术需多中心验证后方可常规用于临床实践。
核心结论
- 沿胸壁截断PTV边距可显著降低靠近胸壁肿瘤的胸壁毒性,1-2级胸壁毒性仅2.8%,且未明显增加局部失败。
研究设计与样本
- 单机构IRB批准的回顾性分析,纳入2009年6月至2016年7月接受SBRT的I期(T1-2aN0M0)NSCLC患者,共225例患者260个肿瘤。
- 采用4D-CT计划,ITV均匀外扩5mm生成PTV,去除与胸壁重叠区域,锥形束CT引导治疗。
- 胸壁毒性按CTCAE v5评估,采用描述性统计分析结局。
主要发现
- 中位随访36.8个月,225例患者中203例的225个肿瘤为周围型。
- 143个肿瘤(63.6%)的ITV位于距胸壁5mm内。
- 中位总剂量48Gy(范围42-60Gy),分4次(范围3-5次)。
- 1-2级胸壁毒性总体发生率2.2%,距胸壁5mm内肿瘤为2.8%。
- 无3/4级胸壁毒性病例,3年局部控制率92.1%(95%CI 87.4%-96.8%)。
关键数值与推荐
- PTV生成方法:ITV均匀外扩5mm,去除与胸壁重叠部分。
- 胸壁毒性评估采用CTCAE version 5。
- 1-2级胸壁毒性总体2.2%,距胸壁5mm内肿瘤2.8%,无3/4级。
- 3年局部控制率92.1%(95%CI 87.4%-96.8%)。
临床怎么用
- 对靠近胸壁的早期NSCLC行SBRT时,可考虑沿胸壁截断PTV以降低胸壁毒性。
- 该技术需多中心验证后方可常规纳入临床实践。
局限性
- 单机构回顾性分析,样本来自单一中心。
- 作者指出需多中心验证后方可普遍纳入临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Chest wall (CW) toxicity is a potentially debilitating complication of stereotactic body radiation therapy for non-small cell lung cancer, occurring in 10% to 40% of patients. Smaller tumor-to-CW distance has been identified as a risk factor for CW toxicity. We report our experience with individualizing the planning target volume (PTV) along the CW in an effort to reduce the volume of this organ at risk receiving 30 Gy to 50 Gy. METHODS AND MATERIALS: We performed an institutional review board-approved retrospective analysis of patients with stage I (T1-2aN0M0) non-small cell lung cancer who received stereotactic body radiation therapy between June 2009 and July 2016. Four-dimensional computed tomography was used for treatment planning. A uniform 5-mm expansion of the internal target volume was generated for the PTV. Areas of overlap with the CW were removed from the PTV. Treatment was delivered with cone beam computed tomography guidance. CW toxicity was assessed per the Common Terminology Criteria for Adverse Events, version 5. Descriptive statistics were used to analyze outcomes. RESULTS: The median follow-up time was 36.8 months. A total of 260 tumors were treated in 225 patients. 225 tumors in 203 patients were peripheral. The internal target volumes for 143 tumors (63.6%) were located within 5 mm of the CW. The median total dose was 48 Gy (range, 42-60 Gy) in 4 fractions (range, 3-5 fractions). The overall rate of grade 1 to 2 CW toxicity was 2.2%, and 2.8% for tumors located within 5 mm of the CW. There were no grade 3/4 cases and no increase in local recurrences with the use of a truncated PTV with a 3-year local control of 92.1% (95% confidence interval, 87.4%-96.8%). CONCLUSIONS: Truncation of the PTV margin along the CW resulted in a marked reduction of CW toxicity for tumors in close proximity to the CW, with only a 2.8% rate of grade 1 to 2 CW toxicity. Despite PTV reduction, there was no appreciable increase in local failures. A multi-institutional validation of this technique is needed before general incorporation into clinical practice.
引用
- Keane FK, Driscoll E, Bowes C, et al. Low Rates of Chest Wall Toxicity When Individualizing the Planning Target Volume Margin in Patients With Early Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy. Pract Radiat Oncol. 2020. PMID: 33239160. doi:10.1016/j.prro.2020.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。